酸性磷酸酶1与3在前列腺癌进展中的相反作用
该系统性综述与荟萃分析评估细胞内ACP1和ACP3表达作为前列腺癌进展生物标志物的作用。结果显示前列腺癌组织中ACP3表达降低(OR 0.30,P=0.006),低ACP3与更高Gleason分级、晚期 stage、淋巴结受累及较差生存相关;而有限研究初步提示ACP1表达升高(HR 2.24,P<0.001)与侵袭性病理特征相关。结论认为ACP3为有利预后标志物,ACP1为潜在负面预后指标。
要点
- 前列腺癌组织中ACP3表达降低(OR 0.30,P=0.006)。
- 低ACP3与更高Gleason分级、晚期肿瘤、淋巴结受累及较差生存相关。
- ACP1表达升高(HR 2.24,P<0.001)与侵袭性病理特征及不良生存相关。
核心结论
- 酸性磷酸酶3(ACP3)在前列腺癌中发挥有利预后生物标志物作用,而ACP1为潜在负面预后指标。
研究设计与样本
- 系统性综述与荟萃分析,评估ACP1和ACP3表达与前列腺癌疾病存在、Gleason分级、肿瘤分期、淋巴结受累及患者生存的关联。
主要发现
- 前列腺癌组织显示ACP3表达降低(OR 0.30,P=0.006)。
- 低细胞内ACP3表达与更高Gleason分级相关(OR 0.44,P=0.031),并与晚期肿瘤分期、淋巴结受累及较差生存相关。
- 来自有限研究的初步证据表明,患者更常显示ACP1表达升高(HR 2.24,P<0.001),且与侵袭性病理特征相关,包括高Gleason分级(HR 3.75,P<0.001)、晚期分期、淋巴结转移及不良生存。
临床怎么用
- ACP3和ACP1表达可能有助于前列腺癌风险分层和精准肿瘤学中的生物标志物驱动决策。
局限性
- 关于ACP1的初步证据来自有限数量的研究,需进一步研究阐明其不同作用并支持其应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the roles of intracellular acid phosphatase 1 (ACP1) and ACP3 expression as biomarkers of prostate cancer progression through a systematic review and meta-analysis assessing associations with disease presence, tumour aggressiveness, and patient prognosis. PATIENTS AND METHODS: A systematic review and meta-analysis were conducted to assess the associations between ACP1 and ACP3 expression and clinical outcomes, including disease presence, Gleason grade, tumour stage, lymph node involvement, and patient survival in prostate cancer. RESULTS: Prostate cancer tissues showed reduced ACP3 expression (odds ratio [OR] 0.30, P = 0.006), and low intracellular ACP3 expression was associated with higher Gleason grade (OR 0.44, P = 0.031), advanced tumour stage, lymph node involvement, and poorer survival. In contrast, preliminary evidence from a limited number of studies indicated that patients more frequently showed elevated ACP1 expression (hazard ratio [HR] 2.24, P < 0.001), which correlated with aggressive pathological features, including high Gleason grade (HR 3.75, P < 0.001), advanced stage, lymph node metastasis, and poor patient survival. CONCLUSION: Acid phosphatase 3 functions as a favourable prognostic biomarker, whereas ACP1 acts as a potential negative prognostic indicator in prostate cancer. Further research is warranted to elucidate their divergent roles and support their utility in biomarker-driven risk stratification and precision oncology.
引用
- Faria, Ferreira-Halder, Peppelenbosch, et al. Opposing roles of acid phosphatase 1 (ACP1) and ACP3 in prostate cancer progression. BJU Int. 2026. PMID: 42952235. doi:10.1111/bju.70515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。